Video game therapy
DeviceVideo game therapy will be delivered with a commercial video game console (X-Box 360 Kinect, Microsoft, Inc., Redmond, WA).
NCT Number: NCT03353974
Multiple Sclerosis (MS) is often characterized by the presence of balance and cognitive impairments. Cognitive functions play a key role in balance control. Simultaneously performing cognitive tasks decreases walking and balance ability (Dual-Task cost). Rehabilitative treatment of patients with MS does not have to consider separately the motor and cognitive aspects. Video-Game Therapy (VGT) is a novel tool that allows a multimodal training approach. VGT typically provides augmented feedback during training that can contribute to learning motor skills. The main objective of this exploratory study will be to test the effects of a commercially available VGT on balance and cognitive function in ambulatory MS patients compared to a standardized balance platform training (BPT). Secondary, we will explore the effects of VGT and BPT on other domains that are usually impaired in MS population and that can be improved by motor rehabilitation, such as psychological well-being, fatigue and Quality of Life.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Sofia Straudi, Ferrara, Emilia-Romagna, Italy
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A group of healthy subjects matched for age and sex will be involved for a comparison on the instrumental data (force platforms).
Video game therapy will be delivered with a commercial video game console (X-Box 360 Kinect, Microsoft, Inc., Redmond, WA).
Balance/rebalancing, postural stability and weight-shifting exercises with and without visual feedback will be administered using a balance platform (Biodex Medical Systems, Inc., Shirley, NY).
Time frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
TUG measures balance and functional mobility.
Time frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
The FSST is a timed test, intended to challenge the rapid change in direction while stepping forward, backward and sideways over a low obstacle.
Time frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
The FRT assesses the subject's stability by measuring the maximum distance an individual can reach forward while standing in a fixed position.
Time frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Clinical tool to assess gait, balance and risk of fall.
Time frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Questionnaire which evaluates the perceived impact of fatigue on the subscales physical, cognitive and psychosocial functioning.
Time frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
This questionnaire assesses the impact of MS on walking ability.
Time frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
This is an health-rated quality of life questionnaire that assesses the impact of MS on physical and psychological functions.
Time frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
This is a 21-item self-report instrument that serves to assess depression severity
Time frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
STAI-Y is an easy-to-use and interpretative tool to detect and measure anxiety.
Time frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Go-No Go task examine the specific capacity to suppress an inadequate reaction.
Time frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
In this task divided attention can be explored with computerized "dual-task" test where two stimuli (visual and acoustic) are required simultaneously
Time frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
The SCWT explores sustained attention and some aspects of executive function.
Time frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
The SDMT consists of orally substituting a number for a pseudorandom sequence of geometric figures as quickly as possible for testing executive functions.
Time frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Force platform measurement are used as objective markers of subjects' balance ability.
Time frame: Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up
Dual cognitive-motor tasks are often used in clinical practice to evaluate the interaction between patients' cognitive and motor ability .
University Hospital of Ferrara
Other
The Role of Video Games Therapy on Balance and Cognitive Functions in Mild to Moderate Impaired Multiple Sclerosis Patients. A Pilot Randomized Controlled Trial.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03963375
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
St Louis, Missouri, United States
View Trial DetailsNCT02511028
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Bethesda, Maryland, United States
View Trial DetailsNCT07175792
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Diepenbeek, Belgium
View Trial DetailsNCT07726667
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Gaziantep, Gaz, Turkey (Türkiye)
View Trial Details